CRUK - Two clinical trials show promise with different targeted drugs for lung cancer
Two drugs targeting different gene faults in lung cancer have shown potential to be better than those already available, according to unpublished clinical trials.
The drug alectinib (Alecensa), which targets a faulty version of the ALK gene, halted the growth of non-small cell lung cancers for 15 months longer than the standard treatment, a drug called crizotinib (Xalkori).
In a separate trial, the drug dacomitinib delayed the growth of tumours carrying a faulty EGFR gene for longer than the drug gefitinib (Iressa), one of the standard targeted medicines for lung cancers with faulty EGFR.
Both trials, presented at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting (link is external) in Chicago, show how new drugs can be developed against already identified targets, potentially with added benefits. And some of the results could change clinical practice.
However, in the case of dacomitinib, this may come with more severe side effects, and experts cautioned that these drugs may not be suitable for some patients.
The phase III ALEX trial (link is external) included 303 patients with advanced non-small cell lung cancer. Their tumour cells carried a version of the ALK gene that’s fused to another gene, triggering uncontrolled cell growth.
Patients had not previously received treatment for their disease, and were then given either alectinib or crizotinib, which is the standard of care treatment.
The newer, more potent alectinib reduced the risk of the disease getting worse or death by 53%. This extended the average time before patients’ disease worsened from 10.4 months with crizotinib to 25.7 months with alectinib.
“This is the first global study to compare alectinib with crizotinib in ALK-positive lung cancer and establishes alectinib as the new standard of care for initial treatment in this setting,” said Dr Alice T. Shaw, Director of Thoracic Oncology at Massachusetts General Hospital Cancer Center in Boston in the US, who led the study.
“Nobody imagined it would be possible to delay advanced lung cancer progression by this much,” she added.
Dr Sanjay Popat, an expert in lung cancer at The Royal Marsden Hospital, said that the ALEX trial was “a major milestone in the treatment of this aggressive disease”.
“It changes the way we should treat our patients with ALK positive lung cancer, a small but important subset of all lung cancers,” he said.
Patients treated with alectinib experienced fewer side effects. And the drug was also better than crizotinib at preventing tumours from spreading to to the brain.
The second trial, called ARCHER (link is external), involved patients with a faulty version of the EGFR molecule inside their tumour cells.
452 patients were included on the phase III trial who had newly diagnosed, advanced stage non-small cell lung cancer. The patients were randomly selected to receive either dacomitinib or gefitinib, one of three drugs in routine use.
Patients who received dacomitinib had a 41% lower chance of their cancer getting worse or death than those treated with gefitinib. This meant the average time taken for their disease to get worse increased from 9.2 months with gefitinib to 14.7 months with dacomitinib. Longer follow up is needed to measure if this ultimately helps patients survive for longer.
“The front-line drug treatment for EGFR mutation positive lung cancer - an uncommon but important lung cancer subtype - has been hotly debated, with three highly effective drugs in routine use: erlotinib, gefitinib, and afatinib,” said Popat.
He added that while it seems that dacomitinib is more effective, this comes at a cost of increased side effects. This means that while dacomitinib offers a potential new treatment option, it might not be right for all patients.
“The second generation of these therapies is more effective, but can also cause greater side effects, so patients and their doctors will need to weigh the risks and benefits,” said ASCO Expert Dr John Heymach.
Latest News from
Age UK comments on Dispatches investigation into Bupa care homes20/06/2017 12:35:00
Age UK has commented on the Channel 4 Dispatches programme from Monday 19 June 2017, 'Bupa Care Homes Undercover'.
Care system 'buckling' says Age UK as major care homes investigation launches15/06/2017 10:35:00
A recent study into the quality of care homes which has sparked a much wider legal investigation has been called 'a manifestation of our buckling social care system' by Age UK.
Diabetes UK - Brits failing to meet the recommended daily allowance of fruit and veg13/06/2017 09:35:00
A new survey* commissioned by Diabetes UK to promote its Food you love healthy eating campaign in Diabetes Week (Sunday 11 June to Saturday 17 June), has found that 66 per cent of adults eat three or fewer portions of fruit and/or vegetables a day – well below the recommended five portions - and 46 per cent won’t eat any fruit at least three days a week.
CRUK - Combining immunotherapies could benefit some aggressive breast cancers09/06/2017 10:15:00
Using two immunotherapy drugs together could help treat some patients with an aggressive form of breast cancer, according to an Australian study.
CRUK - New chemotherapy approach offers breast cancer patients a better quality of life07/06/2017 12:10:00
The chemotherapy drug capecitabine gives patients a better quality of life and is as effective at preventing breast cancer from returning as the alternative regimen called CMF, when given following epirubicin.
CRUK - Adding abiraterone to standard treatment improves prostate cancer survival by 40 per cent06/06/2017 10:35:00
Adding abiraterone to hormone therapy at the start of treatment for prostate cancer improves survival by 37 per cent, according to the results of one of the largest ever clinical trials for prostate cancer presented at the 2017 ASCO Annual Meeting in Chicago and published in the New England Journal of Medicine on Saturday.
British Red Cross - Manchester attack – What happens after05/06/2017 16:15:00
An edition of the BRC’s Newsthink encourages young people to consider ways that the public helped each other after the explosion. It also explores the role of practical help and emotional support during and after an emergency.
British Red Cross launches new UK Solidarity Fund05/06/2017 15:20:00
The British Red Cross has launched a new UK Solidarity Fund to help the victims of terror anywhere in the UK following Saturday’s attack in London.